Raia DrogasilBSP:RADL3 +3.53%91 Return-on-Tangible-Equity is 11.99% as of Mar. 2026, which is 56% below its 10-year median of 27.38. GuruFocus rates BSP:RADL3 with a GF Score™ of 91/100 and a GF Value™ of R$29.98 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 580 Healthcare Providers & Services companies, Raia Drogasil ranks better than 73.97% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Raia Drogasil's annualized net income for the quarter that ended in Mar. 2026 was R$636 Mil. Raia Drogasil's average shareholder tangible equity for the quarter that ended in Mar. 2026 was R$5,303 Mil. Therefore, Raia Drogasil's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 11.99%.
The historical rank and industry rank for Raia Drogasil's Return-on-Tangible-Equity or its related term are showing as below:
BSP:RADL3'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 16.47 Med: 27.38 Max: 30.42
Current: 26.23
During the past 13 years, Raia Drogasil's highest Return-on-Tangible-Equity was 30.42%. The lowest was 16.47%. And the median was 27.38%.
BSP:RADL3's Return-on-Tangible-Equity is ranked better than 73.97% of 580
companies
in the Healthcare Providers & Services industry
Industry Median: 10.065
vs BSP:RADL3: 26.23
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Raia Drogasil Return-on-Tangible-Equity Related Terms
Raia Drogasil Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Raia Drogasil's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.99% mean?
Raia Drogasil (BSP:RADL3) has a Return-on-Tangible-Equity of 11.99% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Raia Drogasil and its competitors. This is 56% below median its historical median of 27.38. Over the past decade, Raia Drogasil's Return-on-Tangible-Equity has ranged from 16.47 to 30.42. According to the industry distribution chart, Raia Drogasil ranks #151 out of 580 companies in the Healthcare Providers & Services industry, placing it in the top 26%.
Is Raia Drogasil's Return-on-Tangible-Equity too high?
Raia Drogasil's current Return-on-Tangible-Equity of 11.99% is 56% below median its 10-year median of 27.38. Over the past 10 years, this metric has ranged from a low of 16.47 to a high of 30.42. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.07. Raia Drogasil's value of 11.99% is 19.1% above this industry median. Based on the distribution chart, Raia Drogasil ranks #151 out of 580 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #151 out of 580 companies for Return-on-Tangible-Equity. This puts Raia Drogasil in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.07. Raia Drogasil's value of 11.99% is 19.1% above this benchmark. Historically, Raia Drogasil's own Return-on-Tangible-Equity has ranged from 16.47 to 30.42 over the past decade. While the company's 10-year median is 27.38 vs. the industry median of 10.07, Raia Drogasil has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.07, based on 580 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current Return-on-Tangible-Equity of 11.99% is 19.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current Return-on-Tangible-Equity is 11.99%, which is 56% below median its own 10-year median of 27.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$29.98, compared to a current price of R$18.77 — trading 37.4% below its estimated fair value. The current Return-on-Tangible-Equity is 11.99%, which is 56% below median its 10-year median of 27.38 and 19.1% above the Healthcare Providers & Services industry median of 10.07. Raia Drogasil's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current Return-on-Tangible-Equity is 11.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$18.77 is trading 37.4% below its estimated GF Value™ of R$29.98.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
Return-on-Tangible-Equity: 11.99% (56% below median its 10-year median of 27.38)
GF Value™: R$29.98 vs. price of R$18.77 (37.4% below fair value)
Industry Position: 19.1% above the Healthcare Providers & Services median (#151 of 580)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
91GF Score
Get the complete analysis for BSP:RADL3
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
